Business Description
Coherus Oncology Inc
NAICS : 541714
SIC : 2836
ISIN : US19249H1032
Total Employee Number:
145Compare
Compare
Traded in other countries / regions
CHRS.USA8C5.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-11-06Description
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.18 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 0.51 | |||||
Debt-to-EBITDA | -0.25 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -8.27 | |||||
Beneish M-Score | 3.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -49 | |||||
3-Year EBITDA Growth Rate | 23.9 | |||||
3-Year EPS without NRI Growth Rate | 23.4 | |||||
3-Year FCF Growth Rate | 27.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.48 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 61.38 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.58 | |||||
9-Day RSI | 52.93 | |||||
14-Day RSI | 48.87 | |||||
3-1 Month Momentum % | -1.2 | |||||
6-1 Month Momentum % | 23.31 | |||||
12-1 Month Momentum % | 123.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.54 | |||||
Quick Ratio | 1.5 | |||||
Cash Ratio | 1.25 | |||||
Days Inventory | 88.12 | |||||
Days Sales Outstanding | 178.63 | |||||
Days Payable | 608.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.4 | |||||
Shareholder Yield % | 76.19 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.06 | |||||
Operating Margin % | -366.55 | |||||
Net Margin % | 397.3 | |||||
EBITDA Margin % | -340.99 | |||||
FCF Margin % | -363.83 | |||||
OCF Margin % | -363.83 | |||||
ROE % | 568.69 | |||||
ROA % | 50.3 | |||||
ROIC % | -213.32 | |||||
3-Year ROIIC % | -70.22 | |||||
ROC (Joel Greenblatt) % | -9934.67 | |||||
ROCE % | -120 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.9 | |||||
Price-to-Owner-Earnings | 1.38 | |||||
PS Ratio | 3.89 | |||||
PB Ratio | 2.93 | |||||
Price-to-Tangible-Book | 7.12 | |||||
EV-to-EBIT | -0.63 | |||||
EV-to-Forward-EBIT | 4.34 | |||||
EV-to-EBITDA | -0.65 | |||||
EV-to-Forward-EBITDA | 4.29 | |||||
EV-to-Revenue | 2.21 | |||||
EV-to-Forward-Revenue | 1.76 | |||||
EV-to-FCF | -0.61 | |||||
Price-to-GF-Value | 1.94 | |||||
| Price-to-Net-Current-Asset-Value | 12.46 | |||||
Earnings Yield (Greenblatt) % | -158.73 | |||||
FCF Yield % | -73.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CHRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coherus Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 46.883 | ||
| EPS (TTM) ($) | 1.67 | ||
| Beta | 1.352 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | 81.03 | ||
| 14-Day RSI | 48.87 | ||
| 14-Day ATR ($) | 0.092213 | ||
| 20-Day SMA ($) | 1.46225 | ||
| 12-1 Month Momentum % | 123.86 | ||
| 52-Week Range ($) | 0.72 - 2.6158 | ||
| Shares Outstanding (Mil) | 154.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coherus Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coherus Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 132 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 17:00 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 41 days | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 09:55 | 1.47 (-3.29%) | ||
| General meeting for 2026 | 2026-05-27 13:30 | 1.64 (-0.61%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 15:00 | 1.61 (+0.63%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 17:00 | 1.75 (-1.13%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.75 (-1.13%) | ||
| Citizens Life Sciences Conference | 2026-03-10 14:50 | 1.93 (+6.04%) |
Show
Entries
Coherus Oncology Inc Frequently Asked Questions
What is Coherus Oncology Inc(CHRS)'s stock price today?
The current price of CHRS is $1.50. The 52 week high of CHRS is $2.62 and 52 week low is $0.72.
When is next earnings date of Coherus Oncology Inc(CHRS)?
The next earnings date of Coherus Oncology Inc(CHRS) is 2026-08-07 Est..
Does Coherus Oncology Inc(CHRS) pay dividends? If so, how much?
Coherus Oncology Inc(CHRS) does not pay dividend.
Guru Commentaries on NAS:CHRS
No articles.
Press Release
Articles on Coherus Oncology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers